Sharps Technology Begins Shipments Across Three Customer Orders Under Previously Announced Purchase Agreements

Rhea-AI Summary

Sharps Technology (NASDAQ: STSS) has initiated commercial shipments across three customer orders, marking its transition to a revenue-generating company. The company delivered its first commercial order of SoloGard syringes under a $50 million supply agreement with a U.S.-based IV flushing solutions leader, starting with a $400,000 order as part of a five-year contract for up to 500 million syringes. Additionally, Sharps shipped SecureGard smart safety syringes worth $100,000 to a Hungarian vaccine provider and commenced delivery of 200,000 units of 1mL low dead space syringes to a Swiss-based provider of cosmetic, dental, and ophthalmic injectable therapies. The total initial purchase commitments amount to approximately $500,000. All products are manufactured at the company's upgraded Hungary-based facility, which features advanced molding and automation technologies to support high-volume production.

Positive

• Secured a significant $50 million, five-year supply agreement for up to 500 million syringes
• Successfully transitioned to a revenue-generating company with initial orders totaling $500,000
• Diversified customer base across multiple markets and geographies
• Manufacturing facility upgraded with advanced molding and automation technologies to support high-volume production

Negative

• Initial revenue of $500,000 is relatively small compared to the potential $50 million agreement
• Manufacturing operations currently limited to single facility in Hungary

Insights

Medical Device Industry Analyst

Sharps Technology transitions to revenue generation with initial commercial shipments of safety syringes, validating manufacturing investments and growth strategy.

Sharps Technology has reached a critical inflection point with the commencement of commercial shipments across three distinct customer orders. This transition from pre-revenue to commercial-stage operations represents a fundamental transformation in the company's business model and risk profile.

The company is executing on three parallel revenue streams: a major $50 million U.S. supply agreement starting with a $400,000 initial order, a $100,000 order from a Hungarian vaccine provider, and a 200,000-unit shipment to a Swiss cosmetic/medical injectable company. This diversification across geographic markets and application types demonstrates commercial validation across multiple product lines.

What's particularly significant is the long-term nature of these relationships. The U.S. supply agreement spans five years with potential for 500 million syringes, providing substantial revenue visibility. The manufacturing investments in Hungary - notably in advanced molding and automation technologies - create operational leverage to support large-scale production.

The technical differentiation of Sharps' products is evident in their specialized applications. The SoloGard line features ultra-low waste design with reuse prevention, while the low dead space syringes for cosmetic applications demonstrate the platform's versatility beyond traditional medical settings. These technical advantages address specific needs in precision delivery and safety compliance.

This commercial transition transforms Sharps from speculative development-stage investment to a company with tangible revenue, manufacturing infrastructure, and contracted future orders. While initial shipments are modest relative to the $50 million agreement's potential, they validate the company's production capabilities and set the stage for scaling operations in late 2025.

Shipments include initial deliveries of SecureGard™ and SoloGard™ smart safety syringes from its Hungary-based manufacturing facility

Deliveries mark the Company’s transition to a commercial-stage, revenue-generating company

NEW YORK, June 04, 2025 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (Nasdaq: “STSS” and “STSSW”) (“Sharps”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class smart-safety syringe products to the healthcare industry, today announced the initiation of shipments for previously announced purchase orders across three customer orders. These shipments mark the Company’s first deliveries of its SecureGard™ and SoloGard™ product lines and its transition to generating commercial revenue.

Sharps has initiated shipment of its first commercial order of Sologard under a previously announced $50 million supply agreement with a U.S.-based leader in IV flushing solutions. The delivery includes customized 10mL SoloGard smart safety syringes manufactured at the Company’s upgraded facility in Hungary. SoloGard is a specialized, FDA- and WHO-approved smart safety syringe featuring ultra-low waste design, standard luer lock compatibility, and re-use prevention technology. This inaugural $400,000 purchase order marks the beginning of a five-year contract to supply up to 500 million syringes and represents the first revenue-generating shipment under the strategic supply agreement. The manufacturing of SoloGard is supported by advanced molding and automation technologies recently invested in by the Company, enabling Sharps to meet the anticipated increase in demand under the agreement during the second half of 2025.

In a separate shipment, Sharps delivered SecureGard smart safety syringes to a Hungarian vaccine provider following a $100,000 purchase order. SecureGard is an FDA- and WHO-approved, CE Mark-certified specialized safety syringe featuring an integrated active recessed safety system, ultra-low waste design, and re-use prevention technology. This marks the customer’s first commercial order and reflects growing global demand for Sharps’ safety syringe technologies. Combined with the SoloGard order, total purchase commitments reached approximately $500,000, establishing Sharps as a revenue-producing company and supporting its transition to commercial operations.

Additionally, Sharps has commenced shipment of 200,000 units of 1mL low dead space syringes to a Swiss-based global provider of cosmetic, dental, and ophthalmic injectable therapies. The syringes will be used in a specialized injection pen for the delivery of Botox and represent the first tranche of a 1-million-unit order. This shipment underscores Sharps’ ability to serve diverse therapeutic markets and meet the technical requirements of premium, differentiated injectable delivery platforms.

“These initial shipments mark a key operational milestone as Sharps officially transitions to a commercial-stage company,” stated Robert Hayes, Chief Executive Officer of Sharps Technology. “For the first time, we are recognizing product revenue across multiple product lines and global markets. This achievement validates years of R&D, strategic planning, and manufacturing investment. We’ve made significant upgrades to our Hungary-based facility to support these deliveries, including the installation of next-generation molding and automation technologies, to ensure we can meet near-term demand and scale rapidly to fulfill long-term contracts. These enhancements not only increase our production capacity, but also elevate the consistency and quality required by our customers.”

All products are being manufactured and shipped from Sharps’ facility in Hungary, which has undergone significant upgrades to support high-volume, high-precision production. The Company continues to build inventory and expand capacity to support current and future purchase commitments under long-term strategic agreements.

Mr. Hayes concluded: “Our progress reflects strong execution by the Sharps team and the strategic value of our manufacturing investments. We look forward to deepening relationships with our partners and driving additional growth in the quarters ahead.”

About Sharps Technology:
Sharps Technology is an innovative medical device and pharmaceutical packaging company offering patented, best-in-class smart-safety syringe products to the healthcare industry. The Company’s product lines focus on providing ultra-low waste capabilities, that incorporate syringe technologies that use both passive and active safety features. Sharps also offers products that are designed with specialized copolymer technology to support the prefillable syringe market segment. The Company has a manufacturing facility in Hungary. For additional information, please visit www.sharpstechnology.com.

FORWARD-LOOKING STATEMENTS:
This press release contains “forward-looking statements”. Forward-looking statements reflect our current view about future events. When used in this press release, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” “poised” or the negative of these terms and similar expressions, as they relate to us or our management, identify forward-looking statements. Such statements, include, but are not limited to, statements contained in this press release relating to our business strategy, our future operating results and liquidity, and capital resources outlook. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. We caution you therefore against relying on any of these forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, our ability to raise capital to fund continuing operations; our ability to protect our intellectual property rights; the impact of any infringement actions or other litigation brought against us; competition from other providers and products; our ability to develop and commercialize products and services; changes in government regulation; our ability to complete capital raising transactions; and other factors relating to our industry, our operations and results of operations. Actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We cannot guarantee future results, levels of activity, performance, or achievements. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.

Investor Contact:
Holdsworth Partners
Adam Holdsworth
Phone: 917-497-9287
Email: IR@sharpstechnology.com

FAQ

What is the value of Sharps Technology's (STSS) first commercial orders in 2025?

Sharps Technology's first commercial orders total approximately $500,000, including a $400,000 SoloGard order and a $100,000 SecureGard order.

What is the size of Sharps Technology's (STSS) supply agreement with the U.S.-based IV flushing solutions company?

Sharps Technology has a $50 million supply agreement over five years to provide up to 500 million syringes to the U.S.-based IV flushing solutions company.

What products does Sharps Technology (STSS) manufacture?

Sharps Technology manufactures smart-safety syringe products including SecureGard and SoloGard, featuring ultra-low waste design, safety features, and re-use prevention technology.

Where does Sharps Technology (STSS) manufacture its products?

Sharps Technology manufactures its products at its upgraded facility in Hungary, which features advanced molding and automation technologies.

Who are the initial customers for Sharps Technology's (STSS) products?

Initial customers include a U.S.-based leader in IV flushing solutions, a Hungarian vaccine provider, and a Swiss-based provider of cosmetic, dental, and ophthalmic injectable therapies.